Vistagen Therapeutics Files 8-K on Financials
Ticker: VTGN · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K with financial updates. Check it out.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 343 Allerton Ave., South San Francisco, California.
Why It Matters
This 8-K filing provides an update on Vistagen Therapeutics' financial performance and condition, which is crucial information for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of Report
- 343 Allerton Ave., South San Francisco, California 94080 (location) — Principal executive offices
- Nevada (jurisdiction) — State of incorporation
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it reports on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on August 13, 2024.
What is the principal business address of Vistagen Therapeutics, Inc.?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California 94080.
In which state was Vistagen Therapeutics, Inc. incorporated?
The company was incorporated in Nevada.
Does this filing mention any former company names or addresses?
Yes, it notes former names 'VistaGen Therapeutics, Inc.' (changed 20110610) and 'Excaliber Enterprises, Ltd.' (changed 20070906), and indicates 'Not Applicable' for former address if changed since last report.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-08-13 16:53:06
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20240813.htm (8-K) — 25KB
- vtgn-20240813xex991.htm (EX-99.1) — 80KB
- image01.jpg (GRAPHIC) — 5KB
- 0001411685-24-000039.txt ( ) — 244KB
- vtgn-20240813.xsd (EX-101.SCH) — 2KB
- vtgn-20240813_lab.xml (EX-101.LAB) — 21KB
- vtgn-20240813_pre.xml (EX-101.PRE) — 12KB
- vtgn-20240813_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 13, 2024, Vistagen Therapeutics, Inc. (the " Company ") issued a press release announcing financial results for its fiscal year 2025 first quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated August 13, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: August 13, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer